INSP vs MBOT
INSP: Inspire Medical Systems provides a unique, neurostimulation-based alternative therapy for obstructive sleep apnea patients who struggle with traditional PAP machines. MBOT: Microbot Medical is an early-stage medical device company developing next-generation robotic endoluminal surgical systems for minimally invasive interventional procedures.
Side-by-side fundamentals
| Metric | INSP | MBOT | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $64.14 | $1.74 | |
| Market cap as of 2026-08-05 | $1.8B | $117M | |
| P/E as of 2026-08-05 | 13.94 | n/a | |
| PEG as of 2026-08-05 | 0.07 | n/a | |
| Net margin as of 2026-08-05 | +14.3% | -3496.2% | INSP higher |
| Gross margin as of 2026-08-05 | +85.8% | +1.9% | INSP higher |
| Operating margin as of 2026-08-05 | +5.2% | -4114.3% | INSP higher |
| ROE as of 2026-08-05 | +18.0% | -21.8% | INSP higher |
| ROA as of 2026-08-05 | +15.3% | -20.7% | INSP higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-05 | +8.9% | -50.0% | INSP higher |
| Revenue CAGR (3y) SEC XBRL | +30.8% | -56.0% | INSP higher |
| Beta as of 2026-08-05 | 0.71 | 1.03 | |
| 1-year return as of 2026-08-04 close | -50.6% | -41.4% | MBOT higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.